CTIS2024-512537-33-00招募中1 期
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab Plus Gemcitabine Plus Oxaliplatin (R- GEMOX) Versus R- GEMOX Alone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma - MO40598
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 265
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Histologically-confirmed DLBCL, not otherwise specified or history of transformation of indolent disease to DLBCL, Relapsed or refractory disease, At least one (>= 1) line of prior systemic therapy, At least one bi-dimensionally measurable lesion, Eastern Cooperative Oncology Group performance status of 0, 1 or 2, Adequate hematological function
排除标准
- •History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products, Contraindication to rituximab, gemcitabine or oxaliplatin, Peripheral neuropathy assessed to be > Grade 1 according to NCI CTCAE v5.0 at enrollment, Prior use of polatuzumab vedotin or a gemcitabine + platinum-based agent combination, Enrollment in any previous or ongoing polatuzumab vedotin trial, Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 2 weeks prior to Cycle 1 Day 1
研究者
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Glofitamab in Combination with Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell LymphomaCTIS2023-506899-27-00F. Hoffmann-La Roche AG245
进行中（未招募）
1 期
A study of a combination of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) compared to Bortezomib with Pomalidomide and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Multiple MyelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004354-21-GRGlaxoSmithKline Research & Development Limited300
进行中（未招募）
1 期
A study of a combination of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) compared to Bortezomib with Pomalidomide and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple MyelomaEUCTR2018-004354-21-ITGLAXOSMITHKLINE RESEARCH AND DEVELOPMENT284
进行中（未招募）
1 期
A study of a combination of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) compared to Bortezomib with Pomalidomide and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Multiple MyelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2018-004354-21-CZGlaxoSmithKline Research & Development Limited284
进行中（未招募）
1 期
A study of a combination of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) compared to Bortezomib with Pomalidomide and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Multiple MyelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004354-21-PLGlaxoSmithKline Research & Development Limited300